12,746 results on '"*ALBENDAZOLE"'
Search Results
2. Efficacy and Safety of MOX/ALB Co-administration in SAC (Moxiped)
- Author
-
Public Health Laboratory Ivo de Carneri and Jennifer Keiser, Prof. Dr.
- Published
- 2024
3. Very prolonged treatment with albendazole of a case of disseminated abdominal cystic echinococcosis
- Author
-
Buscemi, Carola, Randazzo, Cristiana, Buscemi, Paolo, Caldarella, Rosalia, Lombardo, Martina, and Buscemi, Silvio
- Published
- 2023
4. Lymphatic filariasis elimination status: 'Wuchereria bancrofti' infections in human populations after five effective rounds of mass drug administration in Zambia
- Author
-
Matapo, Belem Blamwell, Mpabalwani, Evans Mwila, Kaonga, Patrick, Simuunza, Martin Chitolongo, Bakyaita, Nathan, Masaninga, Freddie, Siyumbwa, Namasiku, Siziya, Seter, Shamilimo, Frank, Muzongwe, Chilweza, Mwase, Enala T, and Sikasunge, Chummy Sikalizyo
- Published
- 2023
5. Eugenol essential oil and nanoemulsion as antihydatic agents with antifibrotic and immunomodulatory effects in cystic echinococcosis
- Author
-
Ahmad, Alzahraa Abdelraouf, Maurice, Maria Naged, Monib, Mohamed El-Salahy M, Soliman, Mahmoud, Al-Thagfan, Sultan S, and Huseein, Enas Abdelhameed Mahmoud
- Published
- 2023
6. Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis (NeuroSolve)
- Author
-
Muhimbili University of Health and Allied Sciences, National Institute for Medical Research, Tanzania, Sokoine University of Agriculture, University of Zambia, University Ghent, and Dario Scaramuzzi, Director
- Published
- 2024
7. Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC (Iverped)
- Author
-
Public Health Laboratory Ivo de Carneri and Jennifer Keiser, Prof. Dr.
- Published
- 2024
8. Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura (FACEITeffic)
- Author
-
Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Uganda and Jennifer Keiser, Prof. Dr.
- Published
- 2024
9. Specific Versus Empirical Anthelminthic Treatment in Eosinophilia (Eosinophilia)
- Author
-
Thareerat Ananchaisarp, Principal Investigator
- Published
- 2024
10. Efficacy and Safety of IVM/ALB Co-administration
- Author
-
Centre Suisse de Recherches Scientifiques en Cote d'Ivoire, Lao Tropical and Public Health Institute, Public Health Laboratory of Pemba, Tanzania, and Jennifer Keiser, Prof. Jennifer Keiser, PhD
- Published
- 2024
11. Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
- Published
- 2024
12. Improving Cognition and Gestational Duration With Targeted Nutrition (COGENT)
- Author
-
Project Peanut Butter, Open Philanthropy, United States Department of Agriculture (USDA), and Ministry of Health and Sanitation, Sierra Leone
- Published
- 2024
13. Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms (ALIVE)
- Author
-
Leiden University Medical Center, Bahir Dar University, Centro de Investigacao em Saude de Manhica, London School of Hygiene and Tropical Medicine, Kenya Medical Research Institute, Laboratorios Liconsa, Universidad de León, and European and Developing Countries Clinical Trials Partnership (EDCTP)
- Published
- 2024
14. Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA) (BOHEMIA)
- Author
-
UNITAID
- Published
- 2024
15. Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
- Author
-
Bill and Melinda Gates Foundation, Imperial College London, London School of Hygiene and Tropical Medicine, Institut de Recherche Clinique du Bénin (IRCB), Institut de Recherche pour le Developpement, Christian Medical College, Vellore, India, Blantyre Institute for Community Ophthalmology (BICO), Swiss Tropical & Public Health Institute, National Institute of Allergy and Infectious Diseases (NIAID), and Judd Walson, Professor in Departments of Global Health, Medicine (Infectious Disease), Pediatrics and Epidemiology
- Published
- 2024
16. HIV And Parasitic Infection (HAPI) Study (HAPI)
- Author
-
Fogarty International Center of the National Institute of Health
- Published
- 2024
17. Efficacy of albendazole against soil-transmitted helminth infections in Ethiopia: a systematic review and meta-analysis.
- Author
-
Sisay, Miseganaw, Damtie, Destaw, and Hailu, Tadesse
- Abstract
Soil-transmitted helminths (STH) are neglected parasites more prevalent in the tropics. Periodic mass distribution of albendazole, is one key strategy to control STHI in endemic areas. However, benzimidazoles have low efficacy against STHI, and there is a lack of information on the magnitude of the problem in Ethiopia. Articles were searched from PubMed using MeSH words, Google Scholar, Web of science, EMBASE and Scopus database to retrieve the data published and available until December 30, 2022. Totally, 107 published articles were retrieved. Only studies conducted in English that reported the efficacy of albendazole against STHI in any year and studies with more than fifty positive cases were included in the present study. The efficacy of albendazole was estimated by its cure rate and egg reduction rate. Excel software was used to extract the name of the authors, the total sample size, number of cured participants, treatment assessment time, STH parasite involved, the study area, and the year of publication. The pooled efficacy of albendazole against STHs was analyzed using comprehensive meta-analysis version 2.2 software. A total of 14 studies (13 for hookworm, 12 for Ascaris lumbricoides, and 12 for Trichuris trichiura) fulfilled the inclusion criteria for the present systematic review and meta-analysis. The total positives for hookworm, A. lumbricoides, and T. trichiura were 1253 (24.9%), 1570 (29.5%), and 1647 (30.6%), respectively. The overall pooled efficacy of albendazole was 92.2% (95% CI 86.2–98.9%) against hookworm, 97.7% (95% CI 96.3–98.6%) against A. lumbricoides, and 38.6% (95% CI 31.0–46.9%) against T. trichiura. In subgroup analysis, the efficacy of albendazole against hookworm was 93.4% (95% CI 85.1–97.2%) in Oromia, 96.7% (95% CI 93.8–98.2%) in Sidama, and 77.2% (95% CI 64.4–86.4%) in Amhara region. Its heterogeneity was high (I
2 = 89.418). The efficacy of albendazole against A. lumbricoides was 98.3% (95% CI 97.0–99.0%) in Oromia and 96.63% (95% CI 93.2–98.3%) in Sidama region. Its heterogeneity was moderate (I2 = 41.5%). Albendazole efficacy against T. trichiura was 39.0% (95% CI 30.4–48.5%) in Oromia and 37.8% (95% CI 21.8–56.9%) in Sidama region with high heterogeneity (I2 = 90.6%). In the present review, albendazole is effective against hookworm and A. lumbricoides but less effective against T. trichiura. Albendazole should therefore be used as a treatment option in hookworm and A. lumbricoides endemic areas. However, alternative drugs should be sought for T. trichiura. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
18. Baseline gut microbiota diversity and composition and albendazole efficacy in hookworm-infected individuals.
- Author
-
Gandasegui, Javier, Fleitas, Pedro E., Petrone, Paula, Grau-Pujol, Berta, Novela, Valdemiro, Rubio, Elisa, Muchisse, Osvaldo, Cossa, Anélsio, Jamine, José Carlos, Sacoor, Charfudin, Brienen, Eric A. T., van Lieshout, Lisette, Muñoz, José, and Casals-Pascual, Climent
- Subjects
STEREOLOGY ,RIBOSOMAL RNA ,TREATMENT effectiveness ,DRUG interactions ,BACTERIAL communities ,GUT microbiome - Abstract
Soil-transmitted helminth (STH) infections account for a significant global health burden, necessitating mass drug administration with benzimidazole-class anthelmintics, such as albendazole (ALB), for morbidity control. However, ALB efficacy shows substantial variability, presenting challenges for achieving consistent treatment outcomes. We have explored the potential impact of the baseline gut microbiota on ALB efficacy in hookworm-infected individuals through microbiota profiling and machine learning (ML) techniques. Our investigation included 89 stool samples collected from hookworm-infected individuals that were analyzed by microscopy and quantitative PCR (qPCR). Of these, 44 were negative by microscopy for STH infection using the Kato-Katz method and qPCR 21 days after treatment, which entails a cure rate of 49.4%. Microbiota characterization was based on amplicon sequencing of the V3–V4 16S ribosomal RNA gene region. Alpha and beta diversity analyses revealed no significant differences between participants who were cured and those who were not cured, suggesting that baseline microbiota diversity does not influence ALB treatment outcomes. Furthermore, differential abundance analysis at the phylum, family and genus levels yielded no statistically significant associations between bacterial communities and ALB efficacy. Utilizing supervised ML models failed to predict treatment response accurately. Our investigation did not provide conclusive insights into the relationship between gut microbiota and ALB efficacy. However, the results highlight the need for future research to incorporate longitudinal studies that monitor changes in the gut microbiota related to the infection and the cure with ALB, as well as functional metagenomics to better understand the interaction of the microbiome with the drug, and its role, if there is any, in modulating anthelmintic treatment outcomes in STH infections. Interdisciplinary approaches integrating microbiology, pharmacology, genetics and data science will be pivotal in advancing our understanding of STH infections and optimizing treatment strategies globally. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Morphological and molecular characterisation of the nematode parasite Graphidioides affinis (Secernentea: Trichostrongylidae) in Patagonian maras, Dolichotis patagonum, kept in a zoo in Sofia, Bulgaria.
- Author
-
Panayotova-Pencheva, Mariana, Laskowski, Zdzisław, and Pyziel, Anna Maria
- Subjects
PARASITIC diseases ,NEMATODES ,ALBENDAZOLE ,ZOOS ,SPECIES - Abstract
Patagonian maras, rodents endemic to South America, are classified as a near-threatened species. Various factors affect their health including parasitic diseases. The aim of this study was to perform morphometric, molecular and phylogenetic characterisation of one such parasitic disease agent, the nematode Graphidioides affinis, specimens of which were found in captive Patagonian maras. In March 2023, 18 Patagonian maras kept at the Sofia Zoo in Bulgaria were investigated with the use of coprological methods. Following the investigation, the animals were dewormed with the use of albendazole. Dead adult nematodes found in the faeces of dewormed maras were collected and preserved in 70% ethanol, and morphometrically, molecularly and phylogenetically analysed. The morphometric analyses confirmed the nematodes to be Graphidioides affinis. The partial nucleotide sequences of the small subunit ribosomal rDNA (SSU), the internal transcribe spacer 2 (ITS2) and the large subunit ribosomal DNA (LSU) of G. affinis were obtained. These are the first available nucleotide sequences of this parasite. The phylogenetic analyses of the species showed its distinctiveness in comparison to other gastrointestinal nematodes, as it was grouped separately. The Patagonian maras kept in a European zoo retained their original parasitofauna which are related to South America. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. In-vitro, anthelminthic effects of Azadirachta indica (Neem), Mallotus philippinensis (Kamala), and Melia azedarach (Bakain) leave extract against Ascaridia galli.
- Author
-
Sadia, H., Imran, M., Shahid, A., Shahbaz, Z., Murtaza, G., Adil, M., Nasir, I., Khalid, M. H., Haider, S., and Saeed, Z.
- Subjects
PLANT extracts ,ALBENDAZOLE ,ADULTS ,MORTALITY ,NEEM ,EGGS - Abstract
The present study was conducted to evaluate the anthelmintic activity of aqueous extracts of Azadirachta indica (Neem), Mallotus philippinensis (Kamala), Melia azedarach (Bakain), and their combination as herbal extracts against Ascaridia galli infection. To determine efficacy, egg hatch test (EHT) and adult motility assay (AMS) were performed using increasing concentrations of 12.5, 25, 50, and 100 mg/ml of aqueous plant extracts, in conjunction with 7.5 mg/ml Albendazole as the positive control and phosphate buffered saline (PBS) as the negative control for up to 15 h. There was 100% mortality achieved with the combined herbal extract (LC
50 = 36.7 µg/ml), whereas mortality with extract from Mallotus 50 philippinensis (LC50 = 41.4 µg/ml), Melia azedarach (LC50 = 147 µg/ml), and 50 50 Azadirachta indica (LC50 = 189 µg/ml) were 87.5%, 62.5%, and 50% respectively, 50 at 15 hours post-exposure. These findings suggest that Azadirachta indica, Mallotus philippinensis, Melia azedarach herbal extracts, or their combination, should be further exploited to control Ascaridia galli infection. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
21. Modeling and comparison of dissolution profiles for different brands of albendazole boluses.
- Author
-
Mekasha, Yesuneh Tefera, Wondie Mekonen, Abibo, Nigussie, Sete, Usure, Rashed Edris, and Feleke, Melaku Getahun
- Subjects
ANIMAL products ,DRUG efficacy ,FEED quality ,ALBENDAZOLE ,QUALITY control ,DRUG solubility ,VETERINARY drugs - Abstract
Background: Addressing critical veterinary drugs, especially drugs with solubility problems like albendazole, and their implications for therapeutic efficacy, in-vitro dissolution studies can indeed provide valuable insights into how different brands of albendazole boluses perform under standardized conditions, helping to assess their dissolution profiles and potential bioavailability. Methods: Six brands of albendazole 300 mg boluses were collected from December 2020 to May 2021 G.C. The laboratory work was conducted from December 2020 to May 2021 in the National Animal Products and Veterinary Drugs and Feed Quality Assessment Centre (APVD-FQAC) laboratories. The collected brands from government veterinary clinics and private veterinary shops were subjected to model independent and dependent parameters. The dissolution test was conducted according to the USP monograph. Results: The study found that none of the six brands met the requirements of the dissolution test, as their API release was less than 80% within the specified 60-minute timeframe according to USP standards. Model independence indicated that only one brand (Alb002 = 3.72) achieved a difference factor of ≤ 15%. The remaining four brands (4/6) did not meet this criterion. However, the similarity factor (f2) revealed that all five brands (5/6) were comparable to the comparator products, with f2 values of 50%. The mean dissolution time results confirmed that three brands (3/6) had the highest dissolution rate and the fastest onset of action. The model-dependent kinetics indicated that the Weibull and Korsemeyer-Peppas models were the best fit for the release of drug substances. Conclusion: The study highlights issues with albendazole boluses' quality, highlighting the need for national in-vitro dissolution studies. These recommendations could improve quality control, streamline regulatory frameworks, and offer practical, cost-effective methods for evaluating drug efficacy and safety, ensuring veterinary pharmaceuticals meet safety and efficacy standards. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis.
- Author
-
Gong, Yuehong, Zhou, Tianjiao, Ma, Ruijia, Yang, Jianhua, Zhao, Yicong, Pan, Meichi, Huang, Zhangjian, Wen, Hao, Jiang, Hulin, and Wang, Jianhua
- Subjects
PYRUVIC acid ,ECHINOCOCCUS granulosus ,NANOPARTICLE size ,LACTATE dehydrogenase ,ENERGY metabolism - Abstract
Background: Albendazole (ABZ) and atovaquone (ATO) achieve killing efficacy on Echinococcus granulosus (Egs) by inhibiting energy metabolism, but their utilization rate is low. This study aims to analyze the killing efficacy of ABZ-ATO loading nanoparticles (ABZ-ATO NPs) on Egs. Methods: Physicochemical properties of NPs were evaluated by ultraviolet spectroscopy and nanoparticle size potentiometer. In vitro experiments exmianed the efficacy of ATO, ABZ, or ATO-ABZ NPs on protoscolex activity, drug toxicity on liver cell LO2, ROS production, and energy metabolism indexes (lactic dehydrogenase, lactic acid, pyruvic acid, and ATP). In vivo of Egs-infected mouse model exmianed the efficacy of ATO, ABZ, or ATO-ABZ NPs on vesicle growth and organ toxicity. Results: Drug NPs are characterized by uniform particle size, stability, high drug loading, and − 21.6mV of zeta potential. ABZ or ATO NPs are more potent than free drugs in inhibiting protoscolex activity. The protoscolex-killing effect of ATO-ABZ NPs was stronger than that of free drugs. In vivo Egs-infected mice experiment showed that ATO-ABZ NPs reduced vesicle size and could protect various organs. The results of energy metabolism showed that ATO-ABZ NPs significantly increased the ROS level and pyruvic acid content, and decreased lactate dehydrogenase, lactic acid content, and ATP production in the larvae. In addition, ATO-ABZ NPs promoted a decrease in DHODH protein expression in protoscolexes. Conclusion: ATO-ABZ NPs exhibits anti-CE in vitro and in vivo, possibly by inhibiting energy production and promoting pyruvic acid aggregation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Identification of Anncaliia algerae in Ascites in an Immunosuppressed Patient, China.
- Author
-
Wang, Zanzan, Li, Dan, Lu, Lingling, Xu, Zhijuan, Ouyang, Guifang, and Sun, Yongcheng
- Subjects
ASCITIC fluids ,ACUTE myeloid leukemia ,VOCAL cords ,SYMPTOMS ,IMMUNOCOMPROMISED patients - Abstract
Anncaliia algerae , a microsporidium, has risen to prominence as an opportunistic pathogen, particularly afflicting individuals who are immunocompromised with conditions such as rheumatoid arthritis, organ transplantation, and hematologic malignancy. Surprisingly, despite its recognized impact, the identification of A algerae in ascitic fluid has not been documented. As such, we pinpointed A algerae as the probable instigator of ascitic accumulation in a patient with a history of acute myeloid leukemia and extended periods of immunosuppressive therapy. For this patient, there were no signs of A algerae –related infections (eg, myositis), vocal cord involvement, or disseminated infection. The presence of A algerae was finally identified by next-generation metagenomic sequencing analysis of the ascitic fluid. Clinical presentation was characterized by elevated C-reactive protein levels (110.7 mg/L), diminished platelet count (48 × 10
9 /L), abdominal distension secondary to ascitic fluid accumulation, and lower limb pain, and it showed marked improvement following a 4-day regimen of sulfamethoxazole/trimethoprim and albendazole. Despite this promising response, the patient succumbed to aspiration of vomitus. This case underscores the importance of considering rarer organisms, such as A algerae infection, in patients who are immunocompromised and present with unexplained ascites accumulation. It highlights the potential effectiveness of sulfamethoxazole/trimethoprim and albendazole in managing such cases. Further research is warranted to elucidate optimal management strategies and improve outcomes in similar clinical scenarios. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
24. A rare presentation of cardiac and hepatic hydatid cysts in a young female: a case report.
- Author
-
Khuanbai, Yerkhanat, Alataev, Bagdat, Kuatbayev, Yermagambet, and Bikhanov, Nurzhan
- Subjects
ECHINOCOCCUS granulosus ,ECHINOCOCCUS multilocularis ,ECHINOCOCCOSIS ,ENDEMIC diseases ,ORGANS (Anatomy) - Abstract
Hydatid disease is an endemic parasitic infection caused by the larval stages of the tapeworm Echinococcus. It is highly endemic in Kazakhstan, with both Echinococcus granulosus and Echinococcus multilocularis widely distributed throughout the country. Hydatid disease can affect almost any organ in the body, with the liver and lung being the most common sites, while cardiac involvement is rare. We report a case of a young female presenting with a 1-year history of stabbing precordial pain, shortness of breath, and weakness. She had a hydatid cyst involving the myocardium of the left ventricle and the left lobe of the liver. The patient underwent surgical resection and received albendazole medication as part of the treatment regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Improving the Solubility, Stability, and Bioavailability of Albendazole through Synthetic Salts.
- Author
-
Yan, Haiying, Zhong, Xueping, and Liu, Yao
- Subjects
FOURIER transform infrared spectroscopy ,X-ray powder diffraction ,FUMARATES ,DIFFERENTIAL scanning calorimetry ,SCANNING electron microscopy ,NUCLEAR magnetic resonance spectroscopy - Abstract
Albendazole (ABZ) is a highly effective yet poorly water-soluble antiparasitic drug known to form salts (ABZ-FMA, ABZ-DTA, and ABZ-HCl) with fumaric acid (FMA), D-tartaric acid (DTA), and hydrochloric acid (HCl). This research utilized a range of analytical techniques, including Fourier transform infrared spectroscopy (FT-IR), nuclear magnetic resonance hydrogen spectroscopy (
1 H NMR), powder X-ray diffraction (PXRD), dynamic vapor sorption (DVS), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM), to validate and characterize the solid-state properties of these drug salts. This study also assessed the solubility and intrinsic dissolution rate (IDR) of these salts under different pH conditions compared to the active pharmaceutical ingredient (API) and conducted stability studies. Moreover, the in vivo pharmacokinetic performance of ABZ salt was evaluated. The results of this study reveal that the new solid form of ABZ is primarily associated with amino acid esters and benzimidazole groups, forming intermolecular interactions. All three ABZ salts significantly improved the solubility and dissolution rate of ABZ, with ABZ-HCl demonstrating the optimal performance. Importantly, the drug salt exhibited robust physical stability when exposed to adverse conditions, including strong light irradiation (4500 ± 500 lux), high humidity (92.5 ± 5% relative humidity), elevated temperatures (50 ± 2 °C), and accelerated test conditions (40 °C/75 ± 5% relative humidity). Lastly, the in vivo pharmacokinetic analysis demonstrated that ABZ salt led to a substantial increase in AUC(0–24) and Cmax compared to ABZ. This elevation in solubility in aqueous solvents signifies that ABZ salt exhibits characteristics that can enhance oral bioavailability and pharmacokinetics. These findings provide potential solutions for the development of more effective and innovative drug formulations. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
26. Baseline gut microbiota diversity and composition and albendazole efficacy in hookworm-infected individuals
- Author
-
Javier Gandasegui, Pedro E. Fleitas, Paula Petrone, Berta Grau-Pujol, Valdemiro Novela, Elisa Rubio, Osvaldo Muchisse, Anélsio Cossa, José Carlos Jamine, Charfudin Sacoor, Eric A. T. Brienen, Lisette van Lieshout, José Muñoz, and Climent Casals-Pascual
- Subjects
Microbiota ,Hookworm ,Albendazole ,Treatment response ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Soil-transmitted helminth (STH) infections account for a significant global health burden, necessitating mass drug administration with benzimidazole-class anthelmintics, such as albendazole (ALB), for morbidity control. However, ALB efficacy shows substantial variability, presenting challenges for achieving consistent treatment outcomes. We have explored the potential impact of the baseline gut microbiota on ALB efficacy in hookworm-infected individuals through microbiota profiling and machine learning (ML) techniques. Our investigation included 89 stool samples collected from hookworm-infected individuals that were analyzed by microscopy and quantitative PCR (qPCR). Of these, 44 were negative by microscopy for STH infection using the Kato-Katz method and qPCR 21 days after treatment, which entails a cure rate of 49.4%. Microbiota characterization was based on amplicon sequencing of the V3–V4 16S ribosomal RNA gene region. Alpha and beta diversity analyses revealed no significant differences between participants who were cured and those who were not cured, suggesting that baseline microbiota diversity does not influence ALB treatment outcomes. Furthermore, differential abundance analysis at the phylum, family and genus levels yielded no statistically significant associations between bacterial communities and ALB efficacy. Utilizing supervised ML models failed to predict treatment response accurately. Our investigation did not provide conclusive insights into the relationship between gut microbiota and ALB efficacy. However, the results highlight the need for future research to incorporate longitudinal studies that monitor changes in the gut microbiota related to the infection and the cure with ALB, as well as functional metagenomics to better understand the interaction of the microbiome with the drug, and its role, if there is any, in modulating anthelmintic treatment outcomes in STH infections. Interdisciplinary approaches integrating microbiology, pharmacology, genetics and data science will be pivotal in advancing our understanding of STH infections and optimizing treatment strategies globally. Graphical Abstract
- Published
- 2024
- Full Text
- View/download PDF
27. Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis
- Author
-
Yuehong Gong, Tianjiao Zhou, Ruijia Ma, Jianhua Yang, Yicong Zhao, Meichi Pan, Zhangjian Huang, Hao Wen, Hulin Jiang, and Jianhua Wang
- Subjects
Atovaquone-albendazole ,Echinococcus Granulosus ,Protoscolex ,Nanoparticles ,Cystic echinococcosis ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Albendazole (ABZ) and atovaquone (ATO) achieve killing efficacy on Echinococcus granulosus (Egs) by inhibiting energy metabolism, but their utilization rate is low. This study aims to analyze the killing efficacy of ABZ-ATO loading nanoparticles (ABZ-ATO NPs) on Egs. Methods Physicochemical properties of NPs were evaluated by ultraviolet spectroscopy and nanoparticle size potentiometer. In vitro experiments exmianed the efficacy of ATO, ABZ, or ATO-ABZ NPs on protoscolex activity, drug toxicity on liver cell LO2, ROS production, and energy metabolism indexes (lactic dehydrogenase, lactic acid, pyruvic acid, and ATP). In vivo of Egs-infected mouse model exmianed the efficacy of ATO, ABZ, or ATO-ABZ NPs on vesicle growth and organ toxicity. Results Drug NPs are characterized by uniform particle size, stability, high drug loading, and − 21.6mV of zeta potential. ABZ or ATO NPs are more potent than free drugs in inhibiting protoscolex activity. The protoscolex-killing effect of ATO-ABZ NPs was stronger than that of free drugs. In vivo Egs-infected mice experiment showed that ATO-ABZ NPs reduced vesicle size and could protect various organs. The results of energy metabolism showed that ATO-ABZ NPs significantly increased the ROS level and pyruvic acid content, and decreased lactate dehydrogenase, lactic acid content, and ATP production in the larvae. In addition, ATO-ABZ NPs promoted a decrease in DHODH protein expression in protoscolexes. Conclusion ATO-ABZ NPs exhibits anti-CE in vitro and in vivo, possibly by inhibiting energy production and promoting pyruvic acid aggregation.
- Published
- 2024
- Full Text
- View/download PDF
28. Clinical implications for the comprehensive interpretation of radiologic and immunodiagnostic tests in patients suspected of parasitic hepatic cyst, a rare case in Korea
- Author
-
Yoo, Jae-Sung, Kang, Min-Kyu, Park, Jung-Gil, Kim, Hyung-Joo, and Choi, Joon-Hyuk
- Published
- 2023
29. Efficacy and Safety of MOX/ALB Co-administration
- Author
-
Centre Suisse de Recherches Scientifiques en Cote d'Ivoire and Jennifer Keiser, Prof. Dr.
- Published
- 2024
30. Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
- Author
-
George Washington University, National Institute of Allergy and Infectious Diseases (NIAID), and Maria Elena Bottazzi PhD, Principal Investigator
- Published
- 2024
31. Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions
- Published
- 2024
32. Solubilization improvement using non-ionic surfactants and phospholipids optimized by an experimental design: Case of albendazole
- Author
-
Bennani, Ismail, Yachi, Lamyae, Chefchaouni, Ali Cherif, Hafidi, Youssef, Moukafih, Badreddine, El Marrakchi, Soufiane, Bandadi, Fatima-Zahra, Fahry, Aicha, El Alaoui, Yassir, Bouatia, Mustapha, Laatiris, Abdelkader, Cherkaoui, Nawal, El Kartouti, Abdeslam, and Rahali, Younes
- Published
- 2024
- Full Text
- View/download PDF
33. Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
- Author
-
National Public Health Institute of Liberia
- Published
- 2023
34. Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults
- Author
-
Universidad Peruana Cayetano Heredia, Lima, Peru
- Published
- 2023
35. Assessment of albendazole efficacy against Ascaris lumbricoides at three sites of Andhra Pradesh, Odisha, and Kerala in India
- Author
-
Vinay Garg, Ankur Garg, Shubha Garg, Sudhir Kumar Jain, Tanzin Dikid, Saurabh Jain, Jitendra Manjhi, Antonio Montresor, and Atul Goel
- Subjects
soil transmitted helminths ,ascaris lumbricoides ,albendazole ,efficacy ,Arctic medicine. Tropical medicine ,RC955-962 - Abstract
Objective: To assess efficacy of albendazole against Ascaris (A.) lumbrìcoides among school-children at three sites of Rajahmundry, Sundergarh and Wayanad. Methods: Sites were selected based on soil-transmitted helminths prevalence, different sociocultural-geographical characteristics and operational feasibility. 9-12 Years old children from 14 schools were included. The study was conducted in two rounds: baseline & follow up survey. All eligible children found positive for A. lumbricoides at baseline were administered supervised single tablet albendazole 400 mg under the National Deworming Day Initiative. During post-treatment follow-up survey, eligible children who provided second stool sample were included in the final analysis. Stool samples were examined using WHO recommended Kato-Katz technique. Efficacy was estimated based on cure rate (CR) and Fecal Egg Count Reduction Rate (FECRR) among children found positive in baseline and follow-up surveys. Results: 328 Out of 625 (52.5%) were found positive for A. lumbricoides in the baseline survey and 85 out of 178 samples (47.8%) during post-treatment follow-up survey. Overall, the estimated CR was 52.2%. FECRR (95% CI) for albendazole was 72.6% (79.2%-66.0%). The FECRR was highest in East Godaveri [89.7% (96.8%-82.6%)], followed by Sundergarh [86.4% (95.3%-77.5%)] and Wayanad [69% (81.7%-56.4%)]. Conclusions: Our study confirmed overall reduction in FEC although with varying albendazole efficacy for A. lumbricoides infection at three different locations in India. However, these finding may be assessed in context of ongoing MDA under Filaria control program and further studies by in vivo as well as in vitro methods are required to reach to a conclusion on possible resistance if any.
- Published
- 2024
- Full Text
- View/download PDF
36. Follow up study of symptomatic human cystic echinococcosis treatment with albendazole and praziquantel, in Uruguay
- Author
-
Daniel Da Rosa, Elisa Figueredo, Michel Rosas, and Fernando Goñi
- Subjects
Cystic echinococcosis ,Medical treatment ,Albendazole ,Praziquantel ,Uruguay ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Cystic echinococcosis (CE) is a chronic disease considered a neglected one. Cystic echinococcosis is endemic in Uruguay and the region. Surgery, using various technical approaches, has the potential to safely remove the cyst(s) and lead to a complete cure in a high number of patients with simple forms of CE. However, surgery may be impractical in patients with multiple cysts in several organs, high surgical risk, or in patients with previous multiple surgeries. In these cases, the pharmacological treatment with the benzimidazolic drug Albendazole (ABZ) alone or combined with Praziquantel (PZQ), has been promising as the best choice to achieve improvement or cure. Methods In this study, we analyze the results obtained on the anti-parasitic treatment of 43 patients diagnosed with CE between the years 2003 and 2020. Patients were treated before and/or after surgery with ABZ or the combination ABZ/PZQ. The standardize protocol of the anti-parasitic drug treatment before surgery was 7 days, 15 days or 1 month depending on the urgency and availability of the surgical procedure. All cases that involved confirmed locations on lungs underwent immediate surgery with minimal pre-treatment when possible. After surgery, the standardize protocol of anti-parasitic drug treatment consisted of six cycles of 30 days each and resting intervals of 15 days in between. ABZ was used in all cases, administered orally, twice daily, at a total dosage of 15 mg/kg/day, with food high in fat content for improved absorption. The follow up was carried out according to WHO-IWGE guidelines for 5 years. Results Of the 43 patients fourteen were ≤ 15 years of age and had a differentiated pre-surgical treatment. From the ≥ 16 years of age, 36 completed the treatments and the 5 years follow up. Four patients changed geographical locations, without a forwarding contact, after the post-surgery treatment. No patient died during the study. Of the 36 patients that completed the study, 32 were treated only with ABZ; 93.75% achieved treatment success as determined by improvement or cure, and 6.25% treatment failure determined by no change or worsening. The last four patients received the ABZ/PZQ combination therapy and achieved 100% treatment success. Conclusion The pharmacological treatment resulted in a good option not only as palliative but also as potentially curative. The main relevance of its use was in cases with previous multiple surgeries or surgeries with potential life-threatening complications due to the number and location of cysts and concurrent comorbidities. A follow-up of at least 5 years would be recommended to assure remission and control of the transmission. More randomized trials are needed to provide clear clinical evidence of different pharmacological treatments for CE.
- Published
- 2024
- Full Text
- View/download PDF
37. In vitro anthelmintic activity and phytochemical characterization of Colchicum autumnale L. corm extract
- Author
-
Zeenath Banu, Shara sherlin Jagannadham, Jangala Akanksha Akanksha, and Aakula Nikshitha Aakula Nikshitha
- Subjects
helminth ,pheretima posthuma ,colchicum autumnale l ,albendazole ,Pharmacy and materia medica ,RS1-441 - Abstract
Helminth infections are prevalent in poverty-stricken areas and developing countries with warm, humid climates and poor sanitary conditions. The limited availability of anthelmintic drugs and the emergence of drug resistance have prompted the search for new treatment options. Medicinal plants, traditionally used for treating various ailments, including parasitic infections, have been explored as sources of novel anthelmintic compounds. To evaluate the preliminary phytochemical analysis and in vitro anthelmintic activity of Colchicum autumnale L. corm extract. The anthelmintic activity of C. autumnale corm extract was tested against Pheretima posthuma (earthworms). Five different concentrations (20, 40, 60, 80, and 100 mg/ml) of the C. autumnale extract were used, alongside the standard drug albendazole at the same concentrations. The time taken for paralysis and death of the worms was recorded. The preliminary phytochemical qualitative analysis of the ethanolic extract showed the presence of alkaloids, carbohydrates, glycosides, saponins, phenols, tannins, and steroids. The study highlighted the potential of C. autumnale extract as a natural anthelmintic agent. The dose-dependent activity suggested that higher concentrations of the extract provided more effective anthelmintic action. However, further research is necessary to establish the optimal dosing, safety, and in vivo efficacy of the extract.
- Published
- 2024
- Full Text
- View/download PDF
38. Albendazole and praziquantel combination versus albendazole alone in children with multiple neurocysticercosis: An open labelled randomized controlled trial
- Author
-
Vijay Rani, Virender K. Gehlawat, and Vandana Arya
- Subjects
albendazole ,neurocysticercosis ,praziquantel ,Medicine - Abstract
Context: The efficacy of the combination of albendazole and praziquantel has not been thoroughly studied in multiple neurocysticercosis in children. Objective: To compare the efficacy and safety of albendazole and praziquantel combination versus albendazole alone in the treatment of children with multiple neurocysticercosis in terms of proportion of cysts undergoing complete resolution or calcification at 6-month follow-up. Materials and Methods: A total of 52 children, aged 1–14 years, with newly diagnosed two or more active neurocysticercosis were randomized to either group A or B. Group A (n = 26) received albendazole plus praziquantel, and Group B (n = 26) received albendazole alone. At the end of 6 months, a repeat MRI brain was performed to see for the resolution of cysts and was classified as complete resolution, calcified, or persistence of viable and noncalcified cysts. Results: The proportion of cysts undergoing complete resolution was higher in Group A (23/60 [38.33%]) than in Group B (19/65 [29.23%]), but the difference was not statistically significant. The proportion of cysts undergoing calcification was also comparable in Group A (20/60 [33.33%]) and Group B (20/65 [30.77%]). Both groups had comparable safety profiles. Conclusion: Albendazole and praziquantel combination therapy is as effective as albendazole alone in terms of complete resolution of viable cysts and calcification of cysts. Trial registration: CTRI/2021/12/038492.
- Published
- 2024
- Full Text
- View/download PDF
39. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study
- Author
-
Adam M. Fimbo, Rajabu Hussein Mnkugwe, Eulambius Mathias Mlugu, Peter P. Kunambi, Alpha Malishee, Omary M.S. Minzi, Appolinary A. R. Kamuhabwa, and Eleni Aklillu
- Subjects
Circulating filarial antigen ,Efficacy ,Ivermectin ,Albendazole ,Lymphatic filariasis ,Microfilariae ,Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Preventive chemotherapy with ivermectin and albendazole (IA) in mass drug administration (MDA) programs for all at-risk populations is the core public health intervention to eliminate lymphatic filariasis (LF). Achieving this goal depends on drug effectiveness in reducing parasite reservoirs in the community to halt transmission. We assessed the efficacy of ivermectin and albendazole in clearing microfilariae and circulating filarial antigens (CFA) following MDA. Methods This community-based prospective study was conducted in Mkinga district, Tanga region, Tanzania, from November 2018 to June 2019. A total of 4115 MDA-eligible individuals were screened for CFA using Filarial test strips. CFA positives were re-examined for microfilariae by microscopy. CFA and microfilariae positive individuals were enrolled and received IA through MDA campaign. The status of microfilariae and CFA was monitored before MDA, and on day 7 and six-month following MDA. The primary efficacy outcomes were the clearance rates of microfilariae on day 7 and six-months, and CFA at 6 months of post-MDA. The McNemar test assessed the proportions of microfilariae positive pre- and post-MDA, while Chi-square tests were utilized to examine factors associated with CFA status six months post-MDA. Results Out of 4115 individuals screened, 239 (5.8%) tested positive for CFA, of whom 11 (4.6%) were also positive for microfilariae. Out of the ten microfilariae-positive individuals available for follow-up on day 7, nine tested negative, yielding a microfilariae clearance rate of 90% [95% confidence interval (CI): 59.6–98.2%]. Participants who tested negative for microfilariae on day 7 remained free of microfilariae six months after MDA. However, those who did not clear microfilariae on day-7 remained positive six-months post-MDA. The McNemar test revealed a significant improvement in microfilariae clearance on day 7 following MDA (P = 0.02). Out of 183 CFA-positive individuals who were available at 6-month follow-up, 160 (87.4%) remained CFA positive, while 23 became CFA negative. The CFA clearance rate at 6 months post-MDA was 12.6% (95% CI: 8.5–8.5%). There was no significant association of variability in ivermectin plasma exposure, measured by maximum concentration or area under the curve, and the clearance status of microfilariae or CFA post-MDA. Conclusions Preventive chemotherapy with IA effectively clears microfilariae within a week. However, it is less effective in clearing CFA at six months of post-MDA. The low clearance rate for filarial antigenemia underscores the need for alternative drug combinations and additional preventive measures to achieve LF elimination by 2030.
- Published
- 2024
- Full Text
- View/download PDF
40. Follow up study of symptomatic human cystic echinococcosis treatment with albendazole and praziquantel, in Uruguay.
- Author
-
Rosa, Daniel Da, Figueredo, Elisa, Rosas, Michel, and Goñi, Fernando
- Subjects
FOLLOW-up studies (Medicine) ,FAT content of food ,ECHINOCOCCOSIS ,ALBENDAZOLE ,HEPATIC echinococcosis ,PRAZIQUANTEL - Abstract
Background: Cystic echinococcosis (CE) is a chronic disease considered a neglected one. Cystic echinococcosis is endemic in Uruguay and the region. Surgery, using various technical approaches, has the potential to safely remove the cyst(s) and lead to a complete cure in a high number of patients with simple forms of CE. However, surgery may be impractical in patients with multiple cysts in several organs, high surgical risk, or in patients with previous multiple surgeries. In these cases, the pharmacological treatment with the benzimidazolic drug Albendazole (ABZ) alone or combined with Praziquantel (PZQ), has been promising as the best choice to achieve improvement or cure. Methods: In this study, we analyze the results obtained on the anti-parasitic treatment of 43 patients diagnosed with CE between the years 2003 and 2020. Patients were treated before and/or after surgery with ABZ or the combination ABZ/PZQ. The standardize protocol of the anti-parasitic drug treatment before surgery was 7 days, 15 days or 1 month depending on the urgency and availability of the surgical procedure. All cases that involved confirmed locations on lungs underwent immediate surgery with minimal pre-treatment when possible. After surgery, the standardize protocol of anti-parasitic drug treatment consisted of six cycles of 30 days each and resting intervals of 15 days in between. ABZ was used in all cases, administered orally, twice daily, at a total dosage of 15 mg/kg/day, with food high in fat content for improved absorption. The follow up was carried out according to WHO-IWGE guidelines for 5 years. Results: Of the 43 patients fourteen were ≤ 15 years of age and had a differentiated pre-surgical treatment. From the ≥ 16 years of age, 36 completed the treatments and the 5 years follow up. Four patients changed geographical locations, without a forwarding contact, after the post-surgery treatment. No patient died during the study. Of the 36 patients that completed the study, 32 were treated only with ABZ; 93.75% achieved treatment success as determined by improvement or cure, and 6.25% treatment failure determined by no change or worsening. The last four patients received the ABZ/PZQ combination therapy and achieved 100% treatment success. Conclusion: The pharmacological treatment resulted in a good option not only as palliative but also as potentially curative. The main relevance of its use was in cases with previous multiple surgeries or surgeries with potential life-threatening complications due to the number and location of cysts and concurrent comorbidities. A follow-up of at least 5 years would be recommended to assure remission and control of the transmission. More randomized trials are needed to provide clear clinical evidence of different pharmacological treatments for CE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment.
- Author
-
Njenga, Sammy M., Kanyi, Henry, Okoyo, Collins, Githinji, Edward, Mwatele, Cassian, Matendechero, Sultani H., Omondi, Wyckliff P., Gitahi, Patrick N., Owaga, Chrispin, Onsongo, Joyce K., and Gass, Katherine
- Subjects
FILARIASIS ,ALBENDAZOLE ,IVERMECTIN ,ONCHOCERCIASIS ,OPERATIONS research - Abstract
The World Health Organization (WHO) endorsed the use of triple-drug mass drug administration (MDA) regimen with ivermectin, diethylcarbamazine (DEC) and albendazole (commonly abbreviated as IDA) to accelerate the elimination of lymphatic filariasis (LF) as a public health problem in settings where onchocerciasis is not co-endemic. The National Programme for Elimination of LF (NPELF) in Kenya was among the first adopters of the IDA-MDA and two annual rounds were provided in 2018 and 2019 to the residents of Lamu County and Jomvu sub-County in the coast region. This study documented the feasibility of successfully delivering the two rounds of IDA-MDA. An operational research study was undertaken to determine efficient sampling strategies, indicators, and the appropriate population groups that could be used for the monitoring and evaluation of LF programs using IDA-MDA for the elimination of the disease as a public health problem. Two cross-sectional surveys were conducted at baseline in 2018 before IDA-MDA and an impact assessment 17 months after the second round of IDA-MDA. The reported epidemiological treatment coverage was at least 80% in all implementation units during each round of IDA-MDA. Blood samples were tested for filarial antigenemia using commercial Filariasis Test Strips (FTS) and any individual found to be positive was tested again at night for the presence of microfilariae in finger prick blood smears using microscopy. The overall prevalence of circulating filarial antigen (CFA) was relatively low at the baseline survey with Jomvu having 1.39% (95% CI: 0.91, 2.11) and Lamu having 0.48% (95% CI: 0.21, 1.13). Significant reduction in CFA prevalence was observed during the impact assessment after two annual rounds of treatment. The overall relative reduction (%) in CFA prevalence following the two rounds of MDA with IDA was significant in both Jomvu (52.45%, Z = -2.46, P < 0.02) and Lamu (52.71%, Z = -1.97, P < 0.05). Heterogeneity, however, was observed in the CFA prevalence reduction between random and purposive clusters, as well as between adult and child populations. The results of the impact assessment survey offered strong evidence that it was safe to stop the IDA-MDA in the two EUs because transmission appears to have been interrupted. It is also important to implement a post-treatment surveillance system which would enable efficient detection of any recrudescence of LF transmission at a sub-evaluation unit level. Our findings show that IDA-MDA may be considered for acceleration of LF elimination in other settings where onchocerciasis is not co-endemic. Author summary: Preventive chemotherapy with antifilarial drugs is currently the mainstay public health intervention recommended for the elimination of lymphatic filariasis (commonly known as elephantiasis) in endemic countries. Two-drug regimen mass drug administration of albendazole plus either diethylcarbamazine or ivermectin has been used widely in most countries since the launch of the Global Programme to Eliminate Lymphatic Filariasis by the World Health Organization in 2000. Safety and efficacy clinical studies conducted in Papua New Guinea have shown that co-administration of three antifilarial drugs namely, ivermectin, diethylcarbamazine and albendazole is superior to the two-drug regimen diethylcarbamazine and albendazole in clearance of microfilariae from the bloodstream. Consequently, the triple-drug regimen was endorsed for accelerating efforts to eliminate lymphatic filariasis as a public health problem in areas where onchocerciasis is not co-endemic. The aim of this study was to assess the feasibility of delivering mass treatment with the triple-drug regimen under programmatic conditions. An operational research study was conducted to determine the optimal sampling strategies, indicator (or set of indicators), and study populations for monitoring and evaluation of lymphatic filariasis elimination programs using the triple-drug regimen mass treatment. Two rounds of mass treatment with the triple-drug regimen were given to the residents of Lamu County (comprising of Lamu East and Lamu West sub-counties) and Jomvu sub-County (in Mombasa) in November 2018 and November 2019. The programme epidemiological treatment coverage was at least 80% in each implementation unit during the two treatment rounds. The preventive treatment resulted in significant reductions in the prevalence of the disease with the number of positive cases being fewer than the threshold recommended for areas where transmission is likely to be no longer sustainable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Human Infection with the Nematode Gongylonema sp.: A Case Report from Bulgaria.
- Author
-
Vuchev, Dimitar, Popova, Galya, and Tomova, Maya
- Subjects
ZOONOSES ,NEMATODE infections ,ALBENDAZOLE ,MUCOUS membranes ,TONGUE - Abstract
We report a case of infection with the zoonotic nematode Gongylonema sp. in a 24-year-old woman from Varna, Bulgaria. Two days before seeking medical attention, the patient had noticed a filamentous mass in her buccal mucosa that migrated when touched with the tongue. She manually removed a thread-like worm from the mucosa near her lower lip. Albendazole was prescribed for three days. The patient had no history of travelling abroad or contact with animals. To our knowledge, this is the sixth case that has been reported in the country. [ABSTRACT FROM AUTHOR]
- Published
- 2024
43. Hidatidosis cardiaca complicada con embolia cerebral: reporte de caso.
- Author
-
Lazo-Soldevilla, Marco A. and Robles-Cabello, Sofía
- Subjects
ECHINOCOCCOSIS ,HOSPITAL emergency services ,ALBENDAZOLE ,EMBOLISMS ,DIAGNOSIS ,DICHOTIC listening tests ,GAS embolism - Abstract
Copyright of Archivos de Cardiología de México is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
44. Assessment of the Therapeutic Impact of Ivermectin Loaded on Solid Lipid Nanoparticles against Muscular Phase of Murine Trichinosis.
- Author
-
Farag, Tahani Ismail, Almotayam, Mona Hussein, Nasr Mohamed, Asmaa Salah, Al-Attar, Al-Sayed R., Aly, Ibrahim, Farag, Shaimaa Mohamed, and Hammad, Samar Kamel
- Subjects
TRICHINELLA spiralis ,TRICHINOSIS ,HEMATOXYLIN & eosin staining ,IVERMECTIN ,BIOMARKERS - Abstract
Background: Trichinosis is acquired through ingesting the infective larvae in pork meat. Drugs employed for the treatment of trichinosis have a limited bioavailability in addition to the adverse side effects. In the current work, the therapeutic effect of ivermectin against experimental muscle trichinosis was evaluated using solid lipid nanoparticles with and without albendazole. Methods: Seven groups of ten albino mice each were created from the 70 total. (GI): normal control, (GII): infected, non-treated, and (GIII): infected treated with albendazole, (GIV): infected treated with ivermectin. (GV) infected treated with solid lipid nanoparticles, (GVI): infected treated with ivermectin loaded on solid lipid nanoparticles, and (GVII): infected and received a combination of albendazole and solid lipid nanoparticles loaded with ivermectin. For the sevenday intestinal phase and the 49-day muscle phase, each group was split into two subgroups of five mice each. The focus of this study is the muscular phase. The mean number of encysted larvae in the muscle tissue was counted for a parasitological evaluation. Using feulgen and hematoxylin and eosin (H&E) stains, all groups were assessed histopathologically and histochemically, respectively. Liver and kidney parameters were also assessed biochemically. Results: The treatment that combined the use of albendazole and ivermectin loaded on solid lipid nanoparticles (GVII) produced the greatest decrease in the count of encysted muscle larvae (92.16%). The improvement in histological, histochemical, and biochemical markers supported these findings. Conclusion: Ivermectin loaded on solid lipid nanoparticles (SLNPS) could be an additional or synergistic therapeutic agent in treating trichinosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. A Case Series and Literature Review of Alveolar Echinococcosis in Kashmir, India: An Emerging Endemic Zone for Echinococcus multilocularis.
- Author
-
Khuroo, Mohammad Sultan, Khuroo, Naira Sultan, and Rather, Ajaz Ahmad
- Subjects
ECHINOCOCCUS multilocularis ,LITERATURE reviews ,BILIARY tract ,LIVER abscesses ,DISEASE prevalence ,GALLBLADDER - Abstract
A prospective study on 110 patients with echinococcosis at Dr. Khuroo's Medical Clinic, Srinagar, Kashmir, India, from March 2019 to April 2024 identified 12 cases (4 males, 8 females; mean age of 46.58 ± 11.97 years) of Alveolar echinococcosis (AE). Two patients were detected through ultrasound examinations carried out for unrelated causes; one presented with features of liver abscess, and nine had pain in the right upper quadrant for a mean period of 2.2 ± 1.79 years. All had the liver as the primary organ involved, with 15 tumor masses of a mean maximum diameter of 9.22 ± 3.21 cm and volume of 426 ± 374.61 cm
3 . Tumors placed centrally had invaded vessels and the biliary tract in eight patients, and those placed peripherally had invaded the liver capsule and adjacent organs in nine patients. Histologic examination of liver biopsies or resected organs revealed necrotic lesions, calcifications, and granulomatous inflammation with slender, thin-walled vesicles of bizarre configuration that stained strongly eosinophilic with periodic acid Schiff. Two patients had segmental liver resections; one was treated with liver aspiration, while the other nine with advanced disease received chemotherapy with albendazole along with praziquantel. Patients showed clinical improvement on a median follow-up of 12 months (range 1 to 60 months); however, MRI T2-weighted images and18 F-FDG-PET-CECT scans in two patients showed active disease on follow-up at one and five years, respectively. A systematic review detected 146 cases of AE in India from 1980 to April 2024. Twenty cases were from foreign countries, mostly from Central Asian republics, and 118 (93.65%) of the remaining 126 Indian patients were permanent residents of Kashmir Valley. The disease affected a population of 79,197 residing in 22 villages from 5 border districts of the valley. These villages were either high in or adjacent to the Himalayan mountain range. Disease prevalence in the affected population was 146.47/105 (males 131.53/105 and females 163.18/105 ) and the incidence was 12.41/105 /year (males 11.16/105 /year and females 13.81/105 /year). Possible causes of the emergence of AE are discussed, and future directions for research to face this challenge arebeen identified. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
46. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study.
- Author
-
Fimbo, Adam M., Mnkugwe, Rajabu Hussein, Mlugu, Eulambius Mathias, Kunambi, Peter P., Malishee, Alpha, Minzi, Omary M.S., Kamuhabwa, Appolinary A. R., and Aklillu, Eleni
- Subjects
IVERMECTIN ,FILARIASIS ,ALBENDAZOLE ,LONGITUDINAL method ,COHORT analysis - Abstract
Background: Preventive chemotherapy with ivermectin and albendazole (IA) in mass drug administration (MDA) programs for all at-risk populations is the core public health intervention to eliminate lymphatic filariasis (LF). Achieving this goal depends on drug effectiveness in reducing parasite reservoirs in the community to halt transmission. We assessed the efficacy of ivermectin and albendazole in clearing microfilariae and circulating filarial antigens (CFA) following MDA. Methods: This community-based prospective study was conducted in Mkinga district, Tanga region, Tanzania, from November 2018 to June 2019. A total of 4115 MDA-eligible individuals were screened for CFA using Filarial test strips. CFA positives were re-examined for microfilariae by microscopy. CFA and microfilariae positive individuals were enrolled and received IA through MDA campaign. The status of microfilariae and CFA was monitored before MDA, and on day 7 and six-month following MDA. The primary efficacy outcomes were the clearance rates of microfilariae on day 7 and six-months, and CFA at 6 months of post-MDA. The McNemar test assessed the proportions of microfilariae positive pre- and post-MDA, while Chi-square tests were utilized to examine factors associated with CFA status six months post-MDA. Results: Out of 4115 individuals screened, 239 (5.8%) tested positive for CFA, of whom 11 (4.6%) were also positive for microfilariae. Out of the ten microfilariae-positive individuals available for follow-up on day 7, nine tested negative, yielding a microfilariae clearance rate of 90% [95% confidence interval (CI): 59.6–98.2%]. Participants who tested negative for microfilariae on day 7 remained free of microfilariae six months after MDA. However, those who did not clear microfilariae on day-7 remained positive six-months post-MDA. The McNemar test revealed a significant improvement in microfilariae clearance on day 7 following MDA (P = 0.02). Out of 183 CFA-positive individuals who were available at 6-month follow-up, 160 (87.4%) remained CFA positive, while 23 became CFA negative. The CFA clearance rate at 6 months post-MDA was 12.6% (95% CI: 8.5–8.5%). There was no significant association of variability in ivermectin plasma exposure, measured by maximum concentration or area under the curve, and the clearance status of microfilariae or CFA post-MDA. Conclusions: Preventive chemotherapy with IA effectively clears microfilariae within a week. However, it is less effective in clearing CFA at six months of post-MDA. The low clearance rate for filarial antigenemia underscores the need for alternative drug combinations and additional preventive measures to achieve LF elimination by 2030. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. In vitro anthelmintic activity and phytochemical characterization of Colchicum autumnale L. corm extract.
- Author
-
Banu, Zeenath, Sharasherlin, Jagannadham, Nikshitha, Aakula, and Akanksha, Jangala
- Subjects
DRUG accessibility ,HELMINTHIASIS ,PARASITIC diseases ,ANTHELMINTICS ,DRUG bioavailability - Abstract
Helminth infections are prevalent in poverty-stricken areas and developing countries with warm, humid climates and poor sanitary conditions. The limited availability of anthelmintic drugs and the emergence of drug resistance have prompted the search for new treatment options. Medicinal plants, traditionally used for treating various ailments, including parasitic infections, have been explored as sources of novel anthelmintic compounds. To evaluate the preliminary phytochemical analysis and in vitro anthelmintic activity of Colchicum autumnale L. corm extract. The anthelmintic activity of C. autumnale corm extract was tested against Pheretima posthuma (earthworms). Five different concentrations (20, 40, 60, 80, and 100 mg/ml) of the C. autumnale extract were used, alongside the standard drug albendazole at the same concentrations. The time taken for paralysis and death of the worms was recorded. The preliminary phytochemical qualitative analysis of the ethanolic extract showed the presence of alkaloids, carbohydrates, glycosides, saponins, phenols, tannins, and steroids. The study highlighted the potential of C. autumnale extract as a natural anthelmintic agent. The dose-dependent activity suggested that higher concentrations of the extract provided more effective anthelmintic action. However, further research is necessary to establish the optimal dosing, safety, and in vivo efficacy of the extract. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. A mini Review of New Potential Therapeutic Strategies Against Trichinellosis.
- Author
-
Ebrahim, Yousra A., Elkhawass, Elham A., Nabil, Zohour I., and El-Shenawy, Nahla S.
- Subjects
TRICHINOSIS ,PARASITIC diseases ,TREATMENT effectiveness ,TRICHINELLA spiralis ,IMMUNOGLOBULINS ,DRUG delivery systems ,SWINE farms - Abstract
Trichinella spiralis is a parasitic nematode transmitted through the consumption of contaminated meat. The study aims to provide comprehensive information on various aspects of trichinellosis, including its manifestations, conventional treatment methods, and emerging antitrichinellosis strategies using nanoparticles is a promising approach to overcoming the challenges posed by conventional trichinellosis treatments. The infection begins when a host ingests meat containing infective larvae of T. spiralis. The adult worms release newborn larvae (NBL) that enter the bloodstream. These NBL invade striated skeletal muscle cells and establish nurse cell-parasite complexes within the muscle tissue. Trichinella causes a public health impact and economic costs related to pig husbandry and food safety. As the prevalence of trichinellosis remains a concern, continued research, surveillance, and public awareness efforts are essential to mitigate the impact of this parasitic infection on human health and the food industry. Pursuing new and effective treatments for trichinellosis remains imperative, and ongoing research efforts are exploring innovative strategies to address the limitations of existing drugs and enhance their therapeutic outcomes. Several studies highlight the potential of specific antigens for developing vaccines that could offer protective immunity against T. spiralis infection, providing valuable insights for future research in parasitology and vaccine development. In conclusion, the integration of nanotechnology and nanoparticles holds promise for revolutionizing drug delivery systems, improving therapeutic outcomes, and offering novel approaches to treat various diseases, including parasitic infections like trichinellosis. Ongoing research in this field is likely to unveil more innovative applications and solutions in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d'Ivoire.
- Author
-
Pillay-Fuentes Lorente, Veshni, Nwogu-Attah, Jacinta N., Steffens, Britta, Bräm, Dominic, Sprecher, Viviane, Hofmann, Daniela, Buettcher, Michael, Pillai, Goonaseelan, Mouksassi, Samer, Coulibaly, Jean, Pfister, Marc, and Keiser, Jennifer
- Subjects
IVERMECTIN ,ALBENDAZOLE ,PUBLIC health ,WHIPWORMS ,PHARMACOKINETICS ,METABOLITES - Abstract
Background and Objective: Trichuriasis caused by the human whipworm Trichuris trichiura poses a significant public health concern. Albendazole-ivermectin co-medication is currently the most effective treatment. Studies conducted in Tanzania and Côte d'Ivoire unveiled differences in efficacy for albendazole-ivermectin combination therapy in both countries. A pharmacometrics approach was used to assess co-medication and study population effects on the pharmacokinetics of the two main metabolites of albendazole. An exploratory exposure-efficacy analysis was also carried out to investigate relationships between exposure measures and the egg reduction rate. Methods: Pharmacokinetic data from studies in Tanzania and Côte d'Ivoire in adolescents (aged 12–19 years) were included in the pharmacometric analysis. Participants received a single dose of either albendazole 400 mg alone or in combination with ivermectin 200 µg/kg. A pharmacometric analysis was performed to investigate the potential effects of the study population and co-administered ivermectin on the apparent clearance of the metabolites of albendazole. Non-linear mixed-effects modeling was conducted with MonolixSuite 2023R1. The pharmacokinetic exposure measures derived from simulations with individual model parameters were used in the exploratory-exposure response analysis. Results: Pharmacokinetic profiles were best described by a two-compartment model for albendazole sulfoxide and a one-compartment model for albendazole sulfone, with a transit compartment and linear elimination. While no co-medication effect was found, apparent clearance of albendazole sulfoxide (albendazole sulfone) in the Tanzanian study population was 75% (46%) higher than that in the Côte d'Ivoire study population. Exposure-efficacy response analyses indicated that peak concentration and the time-above-exposure threshold were associated with the egg reduction rate. Conclusions: Study population but not co-administered ivermectin showed an effect on apparent clearance of albendazole sulfoxide and albendazole sulfone. Polymorphisms in drug-metabolizing enzymes and host-parasite interaction may explain this result. Difference in drug exposure did not explain the disparate efficacy responses in Tanzania and Côte d'Ivoire. Peak concentration and time-above-threshold were exposure measures associated with the egg reduction rate. Further studies evaluating genetic and resistance patterns in various regions in Africa are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Dual drug‐loaded polymeric mixed micelles for ovarian cancer: Approach to enhanced therapeutic efficacy of albendazole and paclitaxel.
- Author
-
Gaikwad, Nikita Maruti, Chaudhari, Pravin Digambar, Shaikh, Karimunnisa Sameer, Chaudhari, Somdatta Y., Pathare, Sandeep S., Shaikh, Amir Afzal, Aljarba, Nada H., Kumer, Ajoy, and Dhara, Bikram
- Subjects
OVARIAN cancer ,CRITICAL micelle concentration ,TREATMENT effectiveness ,MICELLES ,ALBENDAZOLE - Abstract
Chemotherapy resistance remains a significant challenge in treating ovarian cancer effectively. This study addresses this issue by utilizing a dual drug‐loaded nanomicelle system comprising albendazole (ABZ) and paclitaxel (PTX), encapsulated in a novel carrier matrix of D‐tocopheryl polyethylene glycol 1000 succinate vitamin E (TPGS), soluplus and folic acid. Our objective was to develop and optimize this nanoparticulate delivery system using solvent evaporation techniques to enhance the therapeutic efficacy against ovarian cancer. The formulation process involved pre‐formulation, formulation, optimization, and comprehensive characterization of the micelles. Optimization was conducted through a 32 factorial design, focusing on the effects of polymer ratios on particle size, zeta potential, polydispersity index (PDI) and entrapment efficiency (%EE). The optimal formulation demonstrated improved dilution stability, as indicated by a critical micelle concentration (CMC) of 0.0015 mg/mL for the TPGS‐folic acid conjugate (TPGS‐FOL). Extensive characterization included differential scanning calorimetry (DSC), nuclear magnetic resonance (NMR), and Fourier‐transform infrared spectroscopy (FTIR). The release profile exhibited an initial burst followed by sustained release over 90 h. The cytotoxic potential of the formulated micelles was superior to that of the drugs alone, as assessed by MTT assays on SKOV3 ovarian cell lines. Additionally, in vivo studies confirmed the presence of both drugs in plasma and tumour tissues, suggesting effective targeting and penetration. In conclusion, the developed TPGS‐Fol‐based nanomicelles for co‐delivering ABZ and PTX show promising results in overcoming drug resistance, enhancing solubility, sustaining drug release, and improving therapeutic outcomes in ovarian cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.